Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome.
about
Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendationsNew ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeClinical Results of Hypomethylating Agents in AML TreatmentClinical development of demethylating agents in hematologyPretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndromeAzacitidine in the management of patients with myelodysplastic syndromes.Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.Epigenetic therapy in allogeneic hematopoietic stem cell transplantation.The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.Myelodysplastic Syndromes: Updates and Nuances.Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes.Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome.Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML.
P2860
Q24605618-FD22D9E4-A65F-4D2C-82BC-3DE95D213038Q26829132-36CAD242-F344-4F83-AFF7-0C256DE16923Q27022725-1210C0D0-B41E-4C8D-9702-4D9DEDA3FA99Q34395179-8B94E751-7BAD-4419-B5BB-819FBD10BC22Q36036263-0509D65C-1D3B-4633-B2C6-3F75C034E649Q36689145-BC39E101-792E-413A-8A14-3D06914B345BQ36768610-A7BF6068-5E8F-4C3E-9885-DFD61ECACDEDQ37707098-454F73CE-124B-4BDF-8F49-3EB783BEB223Q38112417-C65C9001-D9E7-4EAE-885F-710023ABE411Q38160051-27231B4C-6A64-4961-8846-EAE8728BC91FQ38965973-357EB781-6C07-4CBC-AFAF-171DAB35BC92Q39527812-FFE6E78C-397E-4241-8BC1-916389ACDF55Q41359251-4DC60A51-60F2-40C7-88DE-BD2D232FE590Q46839402-9C59B520-EE87-4941-B73B-C35EAEAEEF2AQ48309941-270C4413-2B72-4AC0-A8AC-3E4521681F11Q50067455-2463EEB2-2AAC-4FC9-BBBE-24E10B20C58FQ53094956-3BB9F5C7-EA15-41ED-B356-6B7422C1DDF7
P2860
Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Feasibility of hypomethylating ...... with myelodysplastic syndrome.
@en
Feasibility of hypomethylating ...... with myelodysplastic syndrome.
@nl
type
label
Feasibility of hypomethylating ...... with myelodysplastic syndrome.
@en
Feasibility of hypomethylating ...... with myelodysplastic syndrome.
@nl
prefLabel
Feasibility of hypomethylating ...... with myelodysplastic syndrome.
@en
Feasibility of hypomethylating ...... with myelodysplastic syndrome.
@nl
P2093
P2860
P356
P1476
Feasibility of hypomethylating ...... with myelodysplastic syndrome
@en
P2093
P2860
P2888
P304
P356
10.1038/BMT.2011.86
P407
P50
P577
2011-04-11T00:00:00Z